Hong Kong Gas Utilities Stock News

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...

Water Oasis Group Limited ( HKG:1161 ) is about to trade ex-dividend in the next 4 days. Typically, the ex-dividend...

BeijingWest Industries International Limited ( HKG:2339 ) shares have continued their recent momentum with a 31% gain...

China Oilfield Services Limited ( HKG:2883 ) shares have had a really impressive month, gaining 29% after a shaky...

United Energy Group Limited ( HKG:467 ) shares have had a really impressive month, gaining 32% after a shaky period...

Key Insights The projected fair value for Towngas Smart Energy is HK$2.91 based on 2 Stage Free Cash Flow to Equity...

As global markets grapple with trade uncertainties and geopolitical tensions, Asian economies have shown resilience, with mixed performance across major indices like Japan's Nikkei and China's CSI 300. In this environment, dividend stocks offer a potential source of steady income for investors seeking stability amidst market volatility.

With a median price-to-earnings (or "P/E") ratio of close to 13x in Hong Kong, you could be forgiven for feeling...

China Overseas Grand Oceans Group Limited ( HKG:81 ) shares have had a really impressive month, gaining 29% after a...

Despite an already strong run, China Life Insurance Company Limited ( HKG:2628 ) shares have been powering on, with a...

Quite a few insiders have dramatically grown their holdings in Kingboard Holdings Limited ( HKG:148 ) over the past 12...

Even if it's not a huge purchase, we think it was good to see that Kwok Lung Hon, the Executive Chairman of Citychamp...

Key Insights Insiders appear to have a vested interest in Tsim Sha Tsui Properties' growth, as seen by their sizeable...

Key Insights The considerable ownership by private companies in Great Eagle Holdings indicates that they collectively...

The Sun Hung Kai Properties Limited ( HKG:16 ) share price has done very well over the last month, posting an excellent...

In January 2026, Ubtech Robotics entered into a Partnership Agreement with Liuzhou Industrial Holding Fund and Liuzhou Industrial Guidance Fund to create a RMB 660 million investment vehicle focused on the intelligent robot industry chain around Liuzhou City’s industrial base. By committing RMB 300 million alongside two major local funds, Ubtech is helping build an ecosystem that targets upstream components, intelligent infrastructure, and broader AI and robotics development through...

Why the Venustech agreement matters for HKBN HKBN (SEHK:1310) has signed a Distribution Framework Agreement with Venustech, giving it exclusive rights in Hong Kong and Macao to distribute Venus Firewall products for the first year of the deal. See our latest analysis for HKBN. HKBN’s 1 month share price return of 14.12% and year to date share price return of 12.48% suggest building momentum, while the 41.55% 1 year total shareholder return points to a much stronger payoff for investors who...

China Hanking Holdings (SEHK:3788) has just combined a leadership shake up with fresh fundraising plans by appointing a new CEO and chairman, while filing a HK$782.8m follow on equity offering at HK$3.80 per share. See our latest analysis for China Hanking Holdings. The leadership overhaul and HK$782.8m follow on offering come after a sharp shift in market expectations, with a 30 day share price return of 33.24% and a very large 1 year total shareholder return. This suggests that momentum has...

Poly Property Group (SEHK:119) caught investor attention after its subsidiary, Shanghai Poly Property, issued a second tranche of 2026 medium term notes. The issuance raised RMB500 million at a 2.95% coupon to replenish funds used for prior debt repayment. See our latest analysis for Poly Property Group. The recent RMB500 million note issuance comes at a time when Poly Property Group’s 90 day share price return of 23.24% and 1 year total shareholder return of 58.44% point to building momentum...

Setting the scene for InSilico Medicine Cayman TopCo InSilico Medicine Cayman TopCo (SEHK:3696) has drawn fresh attention after recent share price moves, with a 1 day return of about 1.6% and a 7 day gain of roughly 4.7%. See our latest analysis for InSilico Medicine Cayman TopCo. The latest moves sit within a much stronger trend, with a year to date share price return of about 58.9% at a current share price of roughly HK$59.7. This suggests momentum has been building as investors reassess...

Chinese regulators have approved Tencent Holdings and other major tech firms to purchase Nvidia's H200 artificial intelligence chips. This is the first time Tencent has received approval to import the H200 chips, which are used for advanced AI workloads. Tencent Holdings (SEHK:700) is trading at HK$621.0, with the share price up 56.1% over the past year and 65.3% over the past three years. The recent approval to access Nvidia's H200 chips arrives as Tencent continues to be a key player in...

Recent share performance and business scale Without a clear single news catalyst, you might be looking at BYD (SEHK:1211) simply because its recent share performance and business size stand out among Hong Kong listed auto and battery groups. Over the past month, BYD shares have returned about 5.9%, while the past 3 months show a modest 1.3% decline. On a 1 year view, the total return figure provided is 14.2%. The company reports revenue of CN¥841.1b and net income of CN¥38.3b. This reflects a...

Harbin Electric (SEHK:1133) has issued a profit forecast for fiscal 2025, indicating an expected increase in net profit tied to higher operating revenue, improved product profitability, and newly secured equipment orders. See our latest analysis for Harbin Electric. Harbin Electric’s recent 1-month share price return of 22.92% and 90-day gain of 52.66% to HK$20.38 suggest momentum is building. Its very large 1-year total shareholder return and strong multi year figures point to a sustained...

Sino Biopharmaceutical recently reported that its independently developed Class I innovative drug TQA3605, a core protein allosteric modulator, met the primary endpoint in a randomized, double-blind, placebo-controlled Phase II trial in chronic hepatitis B patients on nucleos(t)ide analogues, significantly improving viral suppression with a generally favorable safety profile. Because no core protein allosteric modulator for hepatitis B is yet approved globally and diagnosis and treatment...